Mark Watling
Overview
Explore the profile of Mark Watling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
470
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chanteux H, MacPherson M, Kramer H, Otoul C, Okagaki T, Rospo C, et al.
Expert Opin Drug Metab Toxicol
. 2024 Jun;
20(8):841-855.
PMID: 38932723
Background: Padsevonil is an antiseizure medication candidate intended to benefit patients with drug-resistant epilepsy. Our investigations aimed at characterizing pharmacokinetics and drug-drug interaction (DDI) profile of padsevonil. Research Design And...
2.
Kramer H, Bicer C, Otoul C, Rospo C, MacPherson M, Watling M, et al.
AAPS J
. 2023 Nov;
26(1):1.
PMID: 37973662
Volumetric absorptive microsampling (VAMS) techniques have gained popularity these last years as innovative tool for collection of blood pharmacokinetic (PK) samples in clinical trials as they offer many advantages over...
3.
Imbimbo B, Watling M, Imbimbo C, Nistico R
Alzheimers Dement
. 2023 Apr;
19(10):4729-4734.
PMID: 37079778
Evaluating potential therapies for Alzheimer's disease (AD) depends on use of biomarkers for appropriate subject selection and monitoring disease progression. Biomarkers that predict onset of clinical symptoms are particularly important...
4.
Imbimbo B, Ippati S, Watling M, Imbimbo C
Pharmacol Res
. 2022 Dec;
187:106631.
PMID: 36586644
According to the β-amyloid (Aβ) hypothesis of Alzheimer's disease (AD), brain Aβ accumulation is the primary cascade event leading to cognitive deficit and dementia. Numerous anti-Aβ drugs either inhibiting production...
5.
Lozupone M, Imbimbo B, Balducci C, Lo Vecchio F, Bisceglia P, Latino R, et al.
Alzheimers Dement
. 2022 Jul;
19(1):353-368.
PMID: 35900209
Human apolipoprotein E (apoE) is a 299-amino acid secreted glycoprotein binding cholesterol and phospholipids, and with three common isoforms (APOE ε2, APOE ε3, and APOE ε4). The exact mechanism by...
6.
Imbimbo B, Balducci C, Ippati S, Watling M
Neural Regen Res
. 2022 Jul;
18(1):117-118.
PMID: 35799522
No abstract available.
7.
Lo Vecchio F, Bisceglia P, Imbimbo B, Lozupone M, Latino R, Resta E, et al.
Ther Adv Chronic Dis
. 2022 Mar;
13:20406223221081605.
PMID: 35321401
Human apolipoprotein E (ApoE) is a 299-amino acid secreted glycoprotein that binds cholesterol and phospholipids. ApoE exists as three common isoforms (ApoE2, ApoE3, and ApoE4) and heterozygous carriers of the...
8.
Imbimbo B, Watling M
Expert Opin Investig Drugs
. 2021 Dec;
30(12):1175-1182.
PMID: 34890262
Introduction: In the last 15 years, huge efforts against Alzheimer's disease (AD) with drugs targeting β-amyloid (Aβ) and tau have produced poor clinical results. Aducanumab, a recently FDA-approved anti-Aβ monoclonal...
9.
Imbimbo B, Ippati S, Watling M, Balducci C
Alzheimers Dement
. 2021 Sep;
18(5):1008-1037.
PMID: 34533272
Introduction: Primary tauopathies are neurological disorders in which tau protein deposition is the predominant pathological feature. Alzheimer's disease is a secondary tauopathy with tau forming hyperphosphorylated insoluble aggregates. Tau pathology...
10.
Imbimbo B, Ippati S, Watling M, Balducci C
Expert Opin Drug Discov
. 2021 Mar;
16(7):727-735.
PMID: 33653187
: As the global burden of Alzheimer's disease (AD) grows, an effective disease-modifying therapy remains a distant prospect following the repeated failure of multiple therapeutics targeting β-amyloid and (it seems)...